Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly subcutaneous MLN1202 in diabetic nephropathy with macroalbuminuria (Phase 2, Slovakia)
2014-005142-21Phase 2Terminated
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing MLN1202 arm with Placebo arm (2 arms). Started Mar 2015; status: terminated.
02
Drugs
plozalizumab
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2014-005142-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005142-21.